Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer

Galalae, Razvan; Martínez, Álvaro; Mate, Tim; Mitchell, C.; Edmundson, Gregory K.; Nuernberg, N.; Eulau, Stephen M.; Gustafson, Gary; Gribble, Michael; Kovács, G.

doi:10.1016/j.ijrobp.2003.08.003

Cited by 206 publications

(90 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are among the best published in this category of locally advanced prostate cancers [11,25,36]. They also compare favourably with exclusive EBRT data published by Zelefsky et al [39,40].…”

Section: Discussionsupporting

confidence: 90%

“…Similar conclusions have been reported when particularly high radiation doses are delivered [11,25].…”

Section: Discussionsupporting

confidence: 87%

“…Numerous papers have been reported on Bt as a boost to EBRT in the treatment of locally advanced prostatic cancer [11,25,36]. Most of the recent works presented the 5 y bned according to the ASTRO criteria and the different groups of intermediate or unfavourable prognosis based on three adverse criteria (PSAO10 ng/ml, Gleason scoreR7 and clinical stageRT2b).…”

Section: Discussionmentioning

confidence: 99%

“…For locally advanced tumours, combinations with external beam radiation therapy (EBRT) are therefore mandatory to obtain 5 y bned between 70 and 90% [11,25]. 192 Ir high dose rate (HDR) Bt use has been encouraged as it takes advantage of the low a/b ratio of 1.5-3 Gy of prostate tumours [38].…”

mentioning

confidence: 99%

See 3 more Smart Citations

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

Nickers¹,

Coppens

Leval

et al. 2006

Radiotherapy and Oncology

View full text Add to dashboard Cite

Background and purpose: To evaluate on 201 locally advanced prostatic cancers prospectively treated in a phase II trial, the efficacy of a combination of external beam radiotherapy (39.6 Gy) and 192 Ir low dose rate brachytherapy (Bt) (40-45 Gy).Patients and methods: Sixty-four patients were included in the intermediate prognosis group with only one of the following adverse factors (PSAO10 ng/ml, Gleason scoreR7 or clinical stageRT2b) and 137 in the unfavourable group when at least two of these factors were present.Results: The actuarial 4 years biochemical no evidence of disease is 82.8% for the entire population. It is, respectively, 97 and 76% in the intermediate and unfavourable prognosis groups (P!0.0001). GradeR3 late urinary complications occurred in 13 patients (6.5%). Eight patients (4%) presented late grade 2 rectal complications but no grades 3-5 was observed.Conclusions: Even if an a/b of 1.5-3 Gy theoretically favours the use of a high dose rate mode of irradiation, the early results presented here are as good as those reported for similar groups of patients with high dose rate treatments. Late toxicity is identical but our urinary toxicity is within the less favourable and rectal toxicity within the most favourable results.We can postulate that while inducing very high hyperdosage regions (V150) mainly focused on the peripheral zone, most of the Bt techniques consist of a more ablative treatment. Many of the radiobiological studies on Bt did not in fact take into account the heterogeneity of irradiation inside the CTV. This study highlights the need to explore pulsed dose rate therapies, permanent implant and new available radioisotopes such as 169 Ytterbium that will offer the safety of low and lower dose rates. The actual late toxicity of the different Bt techniques is not yet inexistent indeed. q

show abstract

Section: Discussionsupporting

confidence: 90%

“…Similar conclusions have been reported when particularly high radiation doses are delivered [11,25].…”

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

Nickers¹,

Coppens

Leval

et al. 2006

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…Results of multicenter studies 5 , 6 , 7 , 8 have shown that brachytherapy delivered as monotherapy or concurrently with external beam radiotherapy yields biochemical control rates similar to other techniques, while showing the lowest rates of long‐term complications to the organs at risk (OAR) (9) . High‐dose‐rate (HDR) brachytherapy, performed with remote afterloaders, has also the additional advantage of potentially allowing dose escalation (10) without increasing considerably OAR toxicities or treatment times.…”

Section: Introductionmentioning

confidence: 99%

Comparison of IPSA and HIPO inverse planning optimization algorithms for prostate HDR brachytherapy

Panettieri

Smith

Mason

et al. 2014

J Applied Clin Med Phys

View full text Add to dashboard Cite

Publications have reported the benefits of using high‐dose‐rate brachytherapy (HDRB) for the treatment of prostate cancer, since it provides similar biochemical control as other treatments while showing lowest long‐term complications to the organs at risk (OAR). With the inclusion of anatomy‐based inverse planning optimizers, HDRB has the advantage of potentially allowing dose escalation. Among the algorithms used, the Inverse Planning Simulated Annealing (IPSA) optimizer is widely employed since it provides adequate dose coverage, minimizing dose to the OAR, but it is known to generate large dwell times in particular positions of the catheter. As an alternative, the Hybrid Inverse treatment Planning Optimization (HIPO) algorithm was recently implemented in Oncentra Brachytherapy V. 4.3. The aim of this work was to compare, with the aid of radiobiological models, plans obtained with IPSA and HIPO to assess their use in our clinical practice. Thirty patients were calculated with IPSA and HIPO to achieve our department's clinical constraints. To evaluate their performance, dosimetric data were collected: Prostate PTV D90(%),V100(%),V150(%), and V200(%), Urethra D10(%), Rectum D2cc(%), and conformity indices. Additionally tumor control probability (TCP) and normal tissue complication probability (NTCP) were calculated with the BioSuite software. The HIPO optimization was performed firstly with Prostate PTV (HIPOPTV) and then with Urethra as priority 1 (HIPOurethra). Initial optimization constraints were then modified to see the effects on dosimetric parameters, TCPs, and NTCPs. HIPO optimizations could reduce TCPs up to 10%–20% for all PTVs lower than 74 cm3. For the urethra, IPSA and HIPOurethra provided similar NTCPs for the majority of volume sizes, whereas HIPOPTV resulted in large NTCP values. These findings were in agreement with dosimetric values. By increasing the PTV maximum dose constraints for HIPOurethra plans, TCPs were found to be in agreement with IPSA without affecting the urethral NTCPs.PACS numbers: 87.55.‐x, 87.55.de, 87.55.dh, 87.53.Jw

show abstract

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer

Kumar

Shelley

Harrison

et al. 2006

Cochrane Database of Systematic Reviews

193

140

View full text Add to dashboard Cite

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer

Cited by 206 publications

References 27 publications

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

Comparison of IPSA and HIPO inverse planning optimization algorithms for prostate HDR brachytherapy

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer

Contact Info

Product

Resources

About